Imatinib - A breakthrough in the treatment of gastrointestinal stromal tumours;Imatinib - Et gennembrud i behandlingen af gastrointestinale stromale tumorer (GIST)

Ugeskrift for Laeger

Volumn 165, Issue 37, 2003, Pages 3503-3507

  Larsen, Jeanett Borregaard ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; FLUORODEOXYGLUCOSE F 18; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; CANCER THERAPY; CASE REPORT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MALE; PATHOLOGY; RADIOGRAPHY; STROMA CELL;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; STROMAL CELLS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0142155235     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
2. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours. Ann Chir Gynaecol 1998;87:278-81.
3. Lehnert T. Gastrointestinal sarcoma (GIST) - a review of surgical management. Ann Chir Gynaecol 1998;87:297-305.
4. Plaat BEC, Hollema H, Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-20.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2000;438:1-12.
6. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Human Pathol 2000;32:578-82.
7. Miettinen M, Virolainen M, Sarloma-Rikala M. Gastrointestinal stromal tumors - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995:19:207-16.
8. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-34.
9. Kindblom LG, Remotti HE, Aldenborg F et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
10. Zsebo KM, Williams DA, Geissler EN et al. Stem cell factor is encoded at the S1 locus of the mouse and is ligand for the c-kit tyrosine kinase receptor. Cell 1990;63:213-24.
11. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
12. Lasota J, Jasinski M, Sarlomo-Rikala M et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
13. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
14. Dufva IH, Birgens H. Ny målrettet molekylaer cancerbehandling ved kronisk myeloid leukaemi og gastrointestinal stromal tumor. Ugeskr Laeger 2001;163:4759-60.
15. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharm Exp Ther 2000;295:139-45.
16. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
17. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
19. Blanke CD, von Mehren M, Joensuu H et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD117). Proc Am Soc Clin Oncol 2001;20:1A.
20. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.